Oral semaglutide fails to slow early Alzheimer’s decline in two phase 3 trials
Two large phase 3 trials found that oral semaglutide 14 mg did not slow cognitive or functional decline over 104 weeks in people with early symptomatic, amyloid-positive Alzheimer’s disease. Semaglutide…